Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Mannkind Corp (NASDAQ:MNKD)

3.79
Delayed Data
As of Aug 31
 -0.13 / -3.32%
Today’s Change
3.25
Today|||52-Week Range
7.88
-27.33%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$1.6B

Company Description

MannKind Corp. is a biopharmaceutical company. It focuses on the discovery, development and commercialization of therapeutic products for diseases, such as diabetes and cancer. The company's product AFREZZA inhalation powder, which is an ultra rapid-acting insulin that is in late-stage clinical investigation for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia. MannKind was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Valencia, CA.

Contact Information

MannKind Corp.
28903 North Avenue Paine
Valencia California 91355
P:(661) 775-5300
Investor Relations:
(661) 295-4784

Employees

Shareholders

Individual stakeholders37.52%
Mutual fund holders14.97%
Other institutional12.84%

Top Executives

Hakan S. EdstromPresident, Chief Executive Officer & Director
Juergen A. MartensChief Operating Officer & Chief Technology Officer
Matthew J. PfefferCFO, Vice President & Head-Investor Relations
Raymond UrbanskiChief Medical Officer
David B. ThomsonSecretary, Vice President & General Counsel